Glucagon Peptide: GlucaGen, Baqsimi, Gvoke and Severe Hypoglycemia Rescue
Glucagon peptide guide covering GCGR biology, GlucaGen, Baqsimi and Gvoke labels, severe hypoglycemia rescue dosing, half-life and key safety limits.
Glucagon is one of the oldest and best-characterized peptide hormones in clinical use, with an evidence profile that is very different from speculative research-market peptides. It is a 29-amino-acid linear peptide secreted by the alpha cells of the pancreatic islets, and it acts as the body's main counter-regulatory hormone, opposing insulin to keep blood glucose from falling too low.
In medicine, synthetic and recombinant glucagon is best known as emergency rescue therapy for severe hypoglycemia. It is sold as injectable kits (GlucaGen, Gvoke and generic glucagon), a ready-to-use nasal powder (Baqsimi), and a prefilled syringe or autoinjector. Injectable glucagon is also labeled as a diagnostic aid that temporarily relaxes the gastrointestinal tract during imaging.
This guide is educational and not medical advice. Glucagon is a prescription medicine used in emergencies. It should be prescribed, stocked, administered and monitored only through qualified medical care and the exact product instructions.
For broader context on how blood-sugar peptides fit together, compare this guide with the GLP-1 receptor agonist class, semaglutide, the amylin analog pramlintide, and the basics of what peptides are.
Glucagon At A Glance
| Question | Evidence-aware answer |
|---|---|
| What is it? | A 29-amino-acid pancreatic peptide hormone and glucagon-receptor (GCGR) agonist. |
| Common products | GlucaGen (Novo Nordisk), Gvoke (Xeris), Baqsimi nasal powder (Eli Lilly) and generic glucagon. |
| Main effect | Raises blood glucose by stimulating hepatic glycogenolysis and gluconeogenesis. |
| Approved use | Rescue treatment of severe hypoglycemia in diabetes; injectable also a GI radiologic diagnostic aid. |
| Status | FDA-approved; initial U.S. approval of glucagon listed as 1960, with newer delivery forms in 2019. |
| Half-life | Short; roughly 8 to 18 minutes for native glucagon by pharmacokinetic studies. |
| Main safety frame | Requires adequate liver glycogen; contraindicated in pheochromocytoma and insulinoma. |
How Glucagon Raises Blood Sugar
Glucagon is the metabolic mirror image of insulin. When blood glucose falls, pancreatic alpha cells release glucagon, which travels to the liver and binds the glucagon receptor (GCGR), a class B G-protein-coupled receptor expressed mainly on hepatocytes. Receptor activation couples through Gs proteins to raise intracellular cyclic AMP, activating protein kinase A.
The downstream result is twofold. Glucagon stimulates glycogenolysis, the breakdown of stored hepatic glycogen into glucose, and it promotes gluconeogenesis, the synthesis of new glucose. Both pathways push glucose out of the liver and into the bloodstream, correcting hypoglycemia within minutes. Per product labels, injectable glucagon also relaxes smooth muscle in the stomach and intestines, which is the basis for its diagnostic use during radiologic imaging.
This mechanism explains both the power and the limits of glucagon rescue. Because the effect depends on releasing stored liver glycogen, glucagon works well in a person with reasonable glycogen reserves but may fail when those reserves are depleted, a point the prescribing information makes explicitly.
Approved Products And Reference Dosing
Glucagon has a long regulatory history. It was discovered in 1923 by Kimball and Murlin, who isolated a hyperglycemic factor from pancreatic extracts, and its primary structure was determined in 1957 by Bromer and colleagues at Lilly Research Laboratories. The injectable hormone has been marketed for decades, with DailyMed labels listing an initial U.S. approval of 1960. Modern, easier-to-use delivery forms arrived in 2019.
The figures below are reference values drawn from FDA-approved labeling. They describe what regulators authorized for emergency use; they are not dosing recommendations, and glucagon should only be given according to the specific product instructions and a clinician's guidance.
| Product | Route and form | Labeled reference dose |
|---|---|---|
| GlucaGen / generic glucagon (kit) | Subcutaneous, intramuscular or intravenous reconstituted injection | 1 mg for severe hypoglycemia in adults and larger children, per label. |
| Gvoke (Xeris) | Ready-to-use subcutaneous injection (prefilled syringe or HypoPen) | 0.5 mg pediatric and 1 mg adult fixed doses, per label. |
| Baqsimi (Eli Lilly) | Intranasal powder, single fixed dose | 3 mg single nasal actuation for ages 1 year and older, per label. |
| Diagnostic aid (injectable) | Intravenous or intramuscular | 0.25 to 2 mg depending on the GI segment being imaged, per label. |
The 2019 approvals of Baqsimi (nasal, July 2019) and Gvoke (subcutaneous, September 2019) addressed a long-standing usability problem: older glucagon emergency kits required reconstituting a lyophilized powder with a diluent under stress, which led to frequent dosing errors. Ready-to-use liquid and nasal forms removed that step.
What The Evidence Shows And Where It Stops
The evidence base for glucagon in severe hypoglycemia is strong and label-backed. Pharmacokinetic studies of intranasal, intramuscular and intravenous glucagon in healthy subjects and people with diabetes established the short plasma half-life and rapid glucose response. Registration trials for Baqsimi and Gvoke demonstrated that the newer delivery systems reliably reversed insulin-induced hypoglycemia, with the large majority of treated episodes resolving within about 15 to 30 minutes.
There are honest limits to keep in view. Native glucagon is metabolically unstable in solution, which historically forced the powder-plus-diluent kit design; its short duration of action means a single rescue dose can be followed by recurrent hypoglycemia if the underlying cause is not addressed, so labels advise giving oral carbohydrate once the patient can swallow and seeking medical help. Glucagon is a rescue tool, not a treatment for the diabetes itself.
Glucagon-receptor biology is also an active research area beyond rescue therapy. Stable glucagon analogs such as dasiglucagon have been studied for hypoglycemia and for use in bi-hormonal artificial pancreas systems, and dual or triple incretin agonists that engage the glucagon receptor alongside GLP-1 are being explored for metabolic disease. Those are distinct molecules and programs; this guide is about glucagon itself, and readers should not assume that emerging analog data applies to the approved rescue product.
Safety Limits
Glucagon's safety profile follows directly from its mechanism. Because it works by mobilizing hepatic glycogen, it can be ineffective when glycogen stores are low, and it carries specific contraindications tied to hormone-secreting tumors.
| Safety issue | Why it matters |
|---|---|
| Depends on liver glycogen | May not work in starvation, prolonged fasting, adrenal insufficiency, chronic hypoglycemia or alcohol-related states, per label. |
| Pheochromocytoma | Contraindicated; glucagon can trigger catecholamine release and dangerous blood-pressure spikes. |
| Insulinoma | Contraindicated or cautioned; an initial glucose rise can provoke rebound insulin release and worsen hypoglycemia. |
| Hypersensitivity | Allergic reactions, including rare anaphylaxis, can occur. |
| Common reactions | Nausea, vomiting and headache are frequent; Baqsimi adds nasal and upper-airway irritation, watery or red eyes and itching. |
| Recurrence risk | Short half-life means hypoglycemia can return; oral carbohydrate and medical follow-up are advised once the patient can eat. |
Severe hypoglycemia is itself a medical emergency, so glucagon's benefit-risk balance in an appropriate patient is favorable. The point is that the rescue dose is not a casual intervention and that the tumor contraindications and the glycogen-dependence are central, not optional, parts of safe use.
How To Evaluate A Glucagon Claim
Ask five questions before trusting a statement about glucagon.
First, which product is being discussed: an older reconstituted kit, GlucaGen, generic glucagon, Gvoke or Baqsimi? Routes and handling differ.
Second, is the context emergency rescue or something else? Glucagon is approved for severe hypoglycemia and as a GI diagnostic aid, not as a wellness, fat-loss or performance peptide.
Third, does the source acknowledge glycogen dependence? A claim that glucagon always works ignores the labeled failure scenarios.
Fourth, is it confusing glucagon with GLP-1 medicines? Glucagon raises blood sugar, whereas GLP-1 drugs and peptides studied for weight loss generally lower it. They share a hormone family name but have opposite glucose effects.
Fifth, is it citing research analogs (like dasiglucagon or glucagon-containing co-agonists) to imply something about the approved rescue product? That is a red flag for overreach.
For the pharmacokinetic side of these comparisons, the peptide half-life guide explains why glucagon's brief duration shapes how it is used.
Bottom Line
Glucagon is a genuine, well-established peptide medicine, not a speculative compound. As a 29-amino-acid pancreatic hormone and glucagon-receptor agonist, it raises blood sugar by mobilizing liver glycogen, which makes it the standard rescue therapy for severe hypoglycemia in diabetes and a diagnostic aid for gastrointestinal imaging.
Its strengths and limits come from the same biology. Glucagon acts fast but briefly, and it depends on adequate liver glycogen, so it can fail in fasting, adrenal insufficiency or chronic hypoglycemia, and it is contraindicated in pheochromocytoma and insulinoma. Modern ready-to-use injectable and nasal forms have made emergency dosing far simpler, but glucagon remains a prescription rescue tool to be used by the label, not a general metabolic or weight peptide.
References
DailyMed. Baqsimi (glucagon) nasal powder prescribing information.
DailyMed. Gvoke (glucagon) injection prescribing information.
DailyMed. Glucagon for injection (kit) prescribing information.
FDA. Baqsimi (glucagon) nasal powder full prescribing information (FDA label).
FDA. Glucagon for injection (Eli Lilly) prescribing information (FDA label).
Hvelplund A, et al. Pharmacokinetics of intranasal, intramuscular and intravenous glucagon in healthy subjects and diabetic patients. Eur J Clin Pharmacol.
Hovelmann U, et al. Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog. Diabetes Care.
Muller TD, et al. The past, present and future physiology and pharmacology of glucagon. PMC.
Nature Reviews Endocrinology. A century of glucagon.
ClinicalTrials.gov. Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children.